CLOVER-1 Phase 2 trial

March 12, 2020March 12, 2020

CLR 131 Shows Anti-tumor Activity, Safety in Difficult-to-treat B-cell Lymphoma Trial

News

Cellectar Biosciences has announced positive trial results demonstrating that its investigational therapy CLR 131 significantly reduced tumor activity, with tolerable safety, in B-cell lymphoma patients who received prior treatments. A “notable” ... Read more

January 7, 2020February 14, 2020

FDA Grants Orphan Drug Status to CLR 131 for Lymphoplasmacytic Lymphoma Treatment

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Cellectar BioSciences‘ experimental therapy CLR 131 for lymphoplasmacytic lymphoma (LPL), or Waldenström’s macroglobulinemia, a rare type of ... Read more

October 4, 2019October 25, 2019

CLR 131 Works to Halt Cancer Growth and Lower Tumor Volume in DLBCL, Early Phase 2 Data Show

News

Cellectar Biosciences’ investigational radiotherapeutic compound, CLR 131, effectively halted cancer progression and reduced tumor size in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), interim data of a Phase 2 trial ... Read more

July 16, 2019

FDA Grants Fast Track Status to Investigational Compound CLR 131 for DLBCL

News

Cellectar Biosciences’ investigational radiotherapeutic compound, CLR 131, has received fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory diffuse large B-cell ... Read more